Terry J. Fry, MD of National Cancer Institute, presents a press brief on Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) at the 58th ASH Annual Meeting in San Diego, CA.
MRD Negative Complete Remissions in Children and Young Adults with ALL
